MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
NovaBay Pharmaceuticals DIO Ratio 2011-2026 | NBY
Annual DIO Ratio NovaBay Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 164 | 183 | 189 | 55.9 | 103 | 68 | 66.1 | 129 | 389 | 391 | 520 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 520 | 55.9 | 206 |
Quarterly DIO Ratio NovaBay Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 63.1 | 77 | 66.9 | - | 398 | 190 | 447 | - | 247 | 181 | 208 | - | 106 | 114 | 146 | - | 104 | 27.2 | 86.4 | - | 112 | 111 | 103 | - | 77 | 53.3 | 143 | - | 88.3 | 65.9 | 107 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 447 | 27.2 | 138 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
43.5 | $ 323.46 | -2.98 % | $ 42.4 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
166 | $ 21.91 | 1.04 % | $ 1.02 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M |  Canada |
 |
Akebia Therapeutics
AKBA
|
147 | $ 1.39 | -10.32 % | $ 357 M | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.57 | -1.44 % | $ 6.83 B |  Spain |
 |
Aquestive Therapeutics
AQST
|
120 | $ 4.21 | -0.71 % | $ 450 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
185 | $ 23.86 | -2.93 % | $ 3.04 B | USA |
 |
BioDelivery Sciences International
BDSI
|
321 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
70.7 | $ 1.54 | 3.02 % | $ 410 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Incyte Corporation
INCY
|
78.4 | $ 95.06 | -2.11 % | $ 18.6 B | USA |
 |
Caladrius Biosciences
CLBS
|
35.8 | - | -16.75 % | $ 25.8 M | USA |